苏州科博瑞君生物医药科技

Coborui is a China-based biotechnology company focused on the discovery and development of innovative small molecule drugs, particularly in the field of targeted protein degradation (TPD). The company utilizes its proprietary technology platform to identify novel E3 ligase ligands and molecular glues, aiming to treat complex diseases such as cancer and autoimmune disorders. By targeting protein-protein interactions and utilizing the ubiquitin-proteasome system, Coborui seeks to develop therapies for targets previously considered undruggable. The company is currently advancing several programs through the pre-clinical stage, supported by a team of experts in medicinal chemistry and biology. Coborui is headquartered in the Suzhou Industrial Park, a major hub for biopharmaceutical innovation in China.